Price target lifted on Cytokinetics

Roth Capital lifted its price target on Cytokinetics (Nasdaq: CYTK) from $13 to $18 sending the stock price up $1.11 to close at $8.01.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.